These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 35005992)

  • 1. Isocitrate Dehydrogenase-Mutated Cholangiocarcinoma: Natural History and Clinical Outcomes.
    Wintheiser G; Zemla T; Shi Q; Tran N; Prasai K; Tella SH; Mody K; Ahn D; Borad M; Bekaii-Saab T; Mahipal A
    JCO Precis Oncol; 2022 Jan; 6():e2100156. PubMed ID: 35005992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic Cholangiocarcinoma.
    Goyal L; Govindan A; Sheth RA; Nardi V; Blaszkowsky LS; Faris JE; Clark JW; Ryan DP; Kwak EL; Allen JN; Murphy JE; Saha SK; Hong TS; Wo JY; Ferrone CR; Tanabe KK; Chong DQ; Deshpande V; Borger DR; Iafrate AJ; Bardeesy N; Zheng H; Zhu AX
    Oncologist; 2015 Sep; 20(9):1019-27. PubMed ID: 26245674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Platinum sensitivity in patients with IDH1/2 mutated vs wild-type intrahepatic cholangiocarcinoma: A propensity score-based study.
    Niger M; Nichetti F; Casadei-Gardini A; Rizzato MD; Pircher C; Bini M; Franza A; Rimini M; Burgio V; Sposetti C; Fornaro L; Rapposelli IG; D'Amico FE; Aprile G; Vivaldi C; Frassineti GL; Milione M; Leoncini G; Cappetta A; Vasile E; Fassan M; Morano F; Perrone F; Tamborini E; Pruneri G; Lonardi S; Mazzaferro V; Pietrantonio F; Di Bartolomeo M; de Braud F
    Int J Cancer; 2022 Oct; 151(8):1310-1320. PubMed ID: 35723131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Outcomes After Progression on First-Line Therapies in IDH1 Mutated Versus Wild-Type Intrahepatic Cholangiocarcinoma Patients.
    Rimini M; Fabregat-Franco C; Persano M; Burgio V; Bergamo F; Niger M; Scartozzi M; Rapposelli IG; Aprile G; Ratti F; Pedica F; Verdaguer H; Rizzato M; Nichetti F; Lai E; Cappetta A; Macarulla T; Fassan M; De Braud F; Pretta A; Simionato F; De Cobelli F; Aldrighetti L; Fornaro L; Cascinu S; Casadei-Gardini A
    Target Oncol; 2023 Jan; 18(1):139-145. PubMed ID: 36689074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of IDH1 mutation on clinical course of patients with intrahepatic cholangiocarcinoma: a retrospective analysis from a German tertiary center.
    Kinzler MN; Jeroch J; Klasen C; Himmelsbach V; Koch C; Finkelmeier F; Trojan J; Zeuzem S; Pession U; Reis H; Demes MC; Wild PJ; Walter D
    J Cancer Res Clin Oncol; 2023 Aug; 149(9):6391-6398. PubMed ID: 36757619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biology of IDH mutant cholangiocarcinoma.
    Wu MJ; Shi L; Merritt J; Zhu AX; Bardeesy N
    Hepatology; 2022 May; 75(5):1322-1337. PubMed ID: 35226770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ivosidenib in IDH1-mutated cholangiocarcinoma: Clinical evaluation and future directions.
    Lavacchi D; Caliman E; Rossi G; Buttitta E; Botteri C; Fancelli S; Pellegrini E; Roviello G; Pillozzi S; Antonuzzo L
    Pharmacol Ther; 2022 Sep; 237():108170. PubMed ID: 35296436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monitoring of Dynamic Changes and Clonal Evolution in Circulating Tumor DNA From Patients With
    Lapin M; Huang HJ; Chagani S; Javle M; Shroff RT; Pant S; Gouda MA; Raina A; Madwani K; Holley VR; Call SG; Dustin DJ; Lanman RB; Meric-Bernstam F; Raymond VM; Kwong LN; Janku F
    JCO Precis Oncol; 2022 Feb; 6():e2100197. PubMed ID: 35171660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutations of isocitrate dehydrogenase 1 and 2 in intrahepatic cholangiocarcinoma.
    Grassian AR; Pagliarini R; Chiang DY
    Curr Opin Gastroenterol; 2014 May; 30(3):295-302. PubMed ID: 24569570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial.
    Zhu AX; Macarulla T; Javle MM; Kelley RK; Lubner SJ; Adeva J; Cleary JM; Catenacci DVT; Borad MJ; Bridgewater JA; Harris WP; Murphy AG; Oh DY; Whisenant JR; Lowery MA; Goyal L; Shroff RT; El-Khoueiry AB; Chamberlain CX; Aguado-Fraile E; Choe S; Wu B; Liu H; Gliser C; Pandya SS; Valle JW; Abou-Alfa GK
    JAMA Oncol; 2021 Nov; 7(11):1669-1677. PubMed ID: 34554208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating oncometabolite D-2-hydroxyglutarate enantiomer is a surrogate marker of isocitrate dehydrogenase-mutated intrahepatic cholangiocarcinomas.
    Delahousse J; Verlingue L; Broutin S; Legoupil C; Touat M; Doucet L; Ammari S; Lacroix L; Ducreux M; Scoazec JY; Malka D; Paci A; Hollebecque A
    Eur J Cancer; 2018 Feb; 90():83-91. PubMed ID: 29274619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-World Data on Ivosidenib in Patients with Previously Treated Isocitrate Dehydrogenase 1-Mutated Intrahepatic Cholangiocarcinomas: An Early Exploratory Analysis.
    Rimini M; Burgio V; Antonuzzo L; Rimassa L; Oneda E; Lavacchi D; Personeni N; Ratti F; Pedica F; Della Corte A; Persano M; De Cobelli F; Aldrighetti L; Scartozzi M; Cascinu S; Casadei-Gardini A
    Target Oncol; 2022 Sep; 17(5):591-596. PubMed ID: 36114954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential isocitrate dehydrogenase 1 and isocitrate dehydrogenase 2 mutation-related landscape in intrahepatic cholangiocarcinoma.
    Xu S; Cao L; Chen R; Ye C; Li Q; Jiang Q; Yan F; Wan M; Zhang X; Ruan J
    Oncologist; 2024 Aug; 29(8):e1061-e1072. PubMed ID: 38842680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FDA Approval Summary: Ivosidenib for the Treatment of Patients with Advanced Unresectable or Metastatic, Chemotherapy Refractory Cholangiocarcinoma with an IDH1 Mutation.
    Casak SJ; Pradhan S; Fashoyin-Aje LA; Ren Y; Shen YL; Xu Y; Chow ECY; Xiong Y; Zirklelbach JF; Liu J; Charlab R; Pierce WF; Fesenko N; Beaver JA; Pazdur R; Kluetz PG; Lemery SJ
    Clin Cancer Res; 2022 Jul; 28(13):2733-2737. PubMed ID: 35259259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating Oncometabolite 2-hydroxyglutarate as a Potential Biomarker for Isocitrate Dehydrogenase (IDH1/2) Mutant Cholangiocarcinoma.
    Lee CL; O'Kane GM; Mason WP; Zhang WJ; Spiliopoulou P; Hansen AR; Grant RC; Knox JJ; Stockley TL; Zadeh G; Chen EX
    Mol Cancer Ther; 2024 Mar; 23(3):394-399. PubMed ID: 38015561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IDH inhibitors in advanced cholangiocarcinoma: Another arrow in the quiver?
    Rizzo A; Ricci AD; Brandi G
    Cancer Treat Res Commun; 2021; 27():100356. PubMed ID: 33799004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping.
    Borger DR; Tanabe KK; Fan KC; Lopez HU; Fantin VR; Straley KS; Schenkein DP; Hezel AF; Ancukiewicz M; Liebman HM; Kwak EL; Clark JW; Ryan DP; Deshpande V; Dias-Santagata D; Ellisen LW; Zhu AX; Iafrate AJ
    Oncologist; 2012; 17(1):72-9. PubMed ID: 22180306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Platinum Sensitivity in
    Doroshow DB; Wei W; Mehrotra M; Sia D; Eder JP; Bindra R; Houldsworth J; LoRusso P; Walther Z
    Cancer Invest; 2023 Sep; 41(7):646-655. PubMed ID: 37505929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PARP inhibitor therapy in patients with IDH1 mutated cholangiocarcinoma.
    Mohan A; Quingalahua E; Gunchick V; Paul S; Kumar-Sinha C; Crysler O; Zalupski MM; Sahai V
    Oncologist; 2024 Aug; 29(8):725-730. PubMed ID: 39036962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comprehensive Immunogenomic Profiling of
    Makawita S; Lee S; Kong E; Kwong LN; Abouelfetouh Z; Danner De Armas A; Xiao L; Murugesan K; Danziger N; Pavlick D; Korkut A; Ross JS; Javle M
    JCO Precis Oncol; 2024 Mar; 8():e2300544. PubMed ID: 38547421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.